Dr. Morgan leads a laboratory focused on improving standard radiation and chemoradiation therapies through the use of novel agents targeting DNA damage response and repair. Her research program prioritizes pre-clinical research with strong clinical/translational relevance with an emphasis on pancreatic cancer. More specific areas of research interest include DNA double-strand break repair, DNA replication, cell cycle and biomarker development.
Areas of Interest
- Tumor immunology
- DNA damage and repair
- DNA replication stress
- Novel molecularly targeted therapeutics
- Pancreatic cancer
Honors & Awards
2016 First place poster award, A. Alfred Taubman Medical Institute 9th Annual Symposium
2012 “Highly Rated Paper” recognition, American Association for Cancer Research Annual Meeting
2011 “Highly Rated Paper” recognition, American Association for Cancer Research Annual Meeting
2004 Invited speaker at the American Association for Cancer Research Annual Meeting
2004 Cancer Biology Training Program, University of Michigan “The role of cell cycle checkpoints in gemcitabine-mediated radiosensitization.”
2001 Granted attendance to the American Association for Cancer Research, Pathobiology of Cancer Workshop.
PhD, West Virginia University, 2002
- U01 (CA216449), National Institutes of Health: Sensitization to chemoradiation by therapeutic targeting of the DNA damage response, 04/2017-03/2022, Role: Co-Investigator
- R01 (CA240515), National Institutes of Health: Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer, 08/2020-07/2025, Role: PI
- UM Pediatric Brain Tumor Initiative: Targeting Ataxia Telangiectasia Mutated for improved radiation therapy efficacy in H3.3 K27M mutant diffuse intrinsic pontine gliomas, 02/2020-03/2021, Role: PI
- R01 (CA156744), National Institutes of Health: The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2, 04/2016-03/2021, Role: PI
Published Articles or Reviews
Selected from 70 publications
- Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, Parsels LA, Shi J, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei YL, Lawrence TS, Zou W, Morgan MA: Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Research 79(15): 3940-3951, 2019. PMC6684166
- Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA: Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1protein in homologous recombination proficient pancreatic cancer. Mol Cancer Ther: 2020. PM33268569
- Zhang Q, Lawrence T, Morgan MA*, Sun Y*. FBXW7 facilitates non-homologous end-joining via K63-linked polyubiquitylation of XRCC4. Molecular Cell, 61:419-33, 2016.(*Equal contribution)
- Parsels L, Tanska D, Parsels J, Zabludoff S, Cuneo K, Lawrence T, Maybaum J*, Morgan M*. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from G2 checkpoint abrogation. Cell Cycle, 15:730-9, 2016.
- Kausar T, Schreiber J, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, and Morgan MA. Sensitization of pancreatic cancers to gemcitabine-chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair. Neoplasia, 17:757-66, 2015.
- Zhang Q, Zhang Y, Parsels JD, Lohse I, Lawrence TS, Pasca di Magliano M, Sun Y, Morgan MA. Fbxw7 deletion accelerates KrasG12D –driven tumorigenesis via Yap accumulation. Neoplasia 11:666-73, 2016.
- Morgan MA, Lawrence TS. Molecular Pathways: Overcoming radiation resistance by targeting the DNA response pathways. Clin Cancer Res, 21:2898-2904, 2015.
- Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Roberson JR, Marsh KB, Davis MA, Maybaum J, Lawrence TS, and Morgan MA. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res, 20:5085-96, 2014.
- Morgan MA, Parsels LA, Maybaum J, and Lawrence TS: Improving the efficacy of chemoradiation with targeted agents. Cancer Discovery, 4:1-12, 2014.